MedTrace Logo

An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib

NCT04764188 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2026-04-13

No results posted yet for this study

Summary

This study aims to characterize the clinical management and outcomes of participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who are being treated with alectinib in real-world clinical practice.

Conditions

Interventions

DRUG

Alectinib

Participants will receive alectinib in accordance with local clinical practice and local labeling.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-LaRoche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-10
Primary Completion
2027-05-10
Completion
2027-05-10

Countries

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Bulgaria
  • Chile
  • China
  • Colombia
  • Croatia
  • Cuba
  • Czechia
  • Finland
  • Israel
  • Italy
  • Lithuania
  • Panama
  • Peru
  • Portugal
  • Romania
  • Russia
  • Serbia
  • Turkey (Türkiye)
  • United Arab Emirates
  • Uruguay
  • Vietnam

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04764188 on ClinicalTrials.gov